Abstract
Background: Cancer is a major health problem worldwide and the major cause of human mortality in the world. The identification of novel structures for effective treatment of cancer is still a major challenge to medicinal chemists. Over the time, important milestones have been achieved in the development of various cancer static drugs for antitumor chemotherapy. Chemotherapy is still highly inadequate, and this necessitates to find novel compounds with potent anticancer activity and minimal or no side effects.
Methods: 5-Amino-3-methyisoxazole 1 was treated with different salicylaldehydes 2a-d refluxing in methanol to get the desired products 2-(3-methylisoxazol)-5-ylimino)methyl)phenols 3a-d. The reduction of these imine intermediates with NaBH4 at room temperature produced the amino phenols 4a-d, which underwent smooth ring closure in the presence of formaldehyde, to give isoxazolyl-1,3- benzoxazine derivatives 5a-d. Compound 5d under Suzuki coupling conditions with different aryl and hetero aryl boronic acids furnished the products 7a-d.
Results: We synthesized the 3,4-dihydro-8-methoxy-3-(3-methylisoxazol-5-yl)-2H-benzo[e][1,3]oxazine derivatives 5a-5d and 7a-7d from readily accessible starting materials in excellent yields. The newly synthesized compounds 5a-5d and 7a-7d were evaluated for in vitro and potent compounds 5b and 7b were screened for in vivo anticancer activity. Compound 5b has shown potential anticancer activity both in vitro and in vivo. Molecular docking studies were also carried out to balance the experimental results.
Conclusion: The structure of all newly synthesized compounds 3-5a-d and 7a-d was confirmed on the basis of IR, 1H NMR, 13C NMR and mass spectral data. Molecular docking studies of compounds 5b and 7b revealed their efficient binding in the hydrophobic pocket in the ATP binding site of EGFR which is consistent with the biological data. Further studies are needed to identify the specific compounds in the series and to develop them as potential anticancer agents.
Keywords: Isoxazolyl-1, 3-benzoxazine, Suzuki-Miyura coupling, anticancer activity, Ehrlich Ascites Carcinoma (EAC), Epidermal Growth Factor Receptor (EGFR).
Graphical Abstract
Letters in Organic Chemistry
Title:Synthesis and Biological Evaluation of 3,4-Dihydro-3-(3-methylisoxazol-5- yl)-2H-benzo[e][1,3]oxazine Derivatives as Anticancer Agents
Volume: 15 Issue: 2
Author(s): Ramu Kakkerla*, Srinivas Marri, M.P.S. Murali Krishna, Parusharamulu Molgara and Y.N. Reddy
Affiliation:
- Department of Chemistry, Satavahana University, Karimnagar-505001, Telangana,India
Keywords: Isoxazolyl-1, 3-benzoxazine, Suzuki-Miyura coupling, anticancer activity, Ehrlich Ascites Carcinoma (EAC), Epidermal Growth Factor Receptor (EGFR).
Abstract: Background: Cancer is a major health problem worldwide and the major cause of human mortality in the world. The identification of novel structures for effective treatment of cancer is still a major challenge to medicinal chemists. Over the time, important milestones have been achieved in the development of various cancer static drugs for antitumor chemotherapy. Chemotherapy is still highly inadequate, and this necessitates to find novel compounds with potent anticancer activity and minimal or no side effects.
Methods: 5-Amino-3-methyisoxazole 1 was treated with different salicylaldehydes 2a-d refluxing in methanol to get the desired products 2-(3-methylisoxazol)-5-ylimino)methyl)phenols 3a-d. The reduction of these imine intermediates with NaBH4 at room temperature produced the amino phenols 4a-d, which underwent smooth ring closure in the presence of formaldehyde, to give isoxazolyl-1,3- benzoxazine derivatives 5a-d. Compound 5d under Suzuki coupling conditions with different aryl and hetero aryl boronic acids furnished the products 7a-d.
Results: We synthesized the 3,4-dihydro-8-methoxy-3-(3-methylisoxazol-5-yl)-2H-benzo[e][1,3]oxazine derivatives 5a-5d and 7a-7d from readily accessible starting materials in excellent yields. The newly synthesized compounds 5a-5d and 7a-7d were evaluated for in vitro and potent compounds 5b and 7b were screened for in vivo anticancer activity. Compound 5b has shown potential anticancer activity both in vitro and in vivo. Molecular docking studies were also carried out to balance the experimental results.
Conclusion: The structure of all newly synthesized compounds 3-5a-d and 7a-d was confirmed on the basis of IR, 1H NMR, 13C NMR and mass spectral data. Molecular docking studies of compounds 5b and 7b revealed their efficient binding in the hydrophobic pocket in the ATP binding site of EGFR which is consistent with the biological data. Further studies are needed to identify the specific compounds in the series and to develop them as potential anticancer agents.
Export Options
About this article
Cite this article as:
Kakkerla Ramu *, Marri Srinivas , Krishna Murali M.P.S. , Molgara Parusharamulu and Reddy Y.N. , Synthesis and Biological Evaluation of 3,4-Dihydro-3-(3-methylisoxazol-5- yl)-2H-benzo[e][1,3]oxazine Derivatives as Anticancer Agents, Letters in Organic Chemistry 2018; 15 (2) . https://dx.doi.org/10.2174/1570178614666170623121207
DOI https://dx.doi.org/10.2174/1570178614666170623121207 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Validation and Applicability of Different Tipranavir/Ritonavir Genotypic Scores in HIV-1 Protease Inhibitor-Experienced Patients
Current HIV Research Biological Applications of ZnO Nanoparticles
Current Molecular Imaging (Discontinued) Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention
Current Drug Targets A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Integrated In Silico-In Vitro Discovery of Lung Cancer-related Tumor Pyruvate Kinase M2 (PKM2) Inhibitors
Medicinal Chemistry Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation?
Current Pharmaceutical Biotechnology Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer
Current Cancer Drug Targets Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Current Molecular Medicine The Sodium-Iodide Symporter
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Recent Advances in Understanding and Exploiting the Activation of Anthracyclines by Formaldehyde
Current Medicinal Chemistry - Anti-Cancer Agents Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) Gallic Acid Improved Amytryptiline Effect in Neuropathic Pain Induced by Partial Sciatic Nerve Ligation (PSNL) in Rats
The Natural Products Journal Celecoxib Upregulates Multidrug Resistance Proteins in Colon Cancer: Lack of Synergy with Standard Chemotherapy
Current Cancer Drug Targets Mechanisms of Angiogenesis: Perspectives from Antiangiogenic Tumor Therapies
Current Angiogenesis (Discontinued) In Vivo Space Radiation-Induced Non-Targeted Responses: Late Effects on Molecular Signaling in Mitochondria
Current Molecular Pharmacology A New Antitumor Agent, (3-chloro-7-methoxyfuro[2,3-b]-quinolin-4-yl)-(4-methoxyphenyl) amine, Loaded in Solid Lipid Nanoparticles: Characterization and Pharmacokinetics
Current Nanoscience